Spots Global Cancer Trial Database for Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
Official Title: Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
Study ID: NCT01679327
Conditions
Study Description
Brief Summary: This study evaluates the relationship of biomarker expression and efficacy of bevacizumab plus chemotherapy in patients with unresectable/metastatic colorectal cancer. Before the treatment, the investigators detect the VEGF-A,VEGF-C,VEGF-D,VEGFR-1,VEGFR-2,VEGFR-3 expression in tumor tissue by IHC and detect those protein expression level in plasma by ELISA. After at least 6 weeks treatment, the investigators detect again VEGF-A,VEGF-C,VEGF-D expression level in plasma by ELISA. The aim of the study is to identify whether those biomarkers could predict Bevacizumab efficacy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Institute&Hospital Chinese Academy of Medical Sciences, Beijing, , China
Contact Details
Name: Yihebali Chi, Doctor
Affiliation: Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Name: Jinwan WANG
Affiliation: Chinese Academy of Medical Sciences
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
